Insecticide Resistance Forces India to Rethink Dengue Strategy Beyond Spraying

Across nine neighborhoods in Pune, researchers tested mosquitoes collected from homes and streets and found something troubling: six of those nine areas harbored Aedes aegypti mosquitoes that no longer died reliably when exposed to permethrin, one of India's standard dengue-control insecticides. The mortality rates told the story. In Warje, only 63 percent of exposed mosquitoes died. In Yerwada, the figure climbed to 91.6 percent. Kothrud remained largely susceptible at 99 percent mortality. But the pattern was clear enough: the chemical that had worked for years was losing its grip.

This 2026 Pune study arrived as confirmation of a much broader crisis. Across India, mosquitoes have been developing resistance to nearly every insecticide in the public-health arsenal. A 2023 review of 43 Indian studies documented widespread resistance to DDT, malathion, deltamethrin, permethrin, lambda-cyhalothrin and temephos. In Delhi-NCR, researchers found that 76 percent of mosquito larvae survived exposure to temephos at the dose the World Health Organization considers lethal. The mosquitoes themselves were evolving, carrying genetic mutations—S989P, V1016G, F1534C, T1520I—that rendered them impervious to poisons that had once been reliable.

The human toll has been mounting. In 2023, India recorded 289,235 dengue cases and 485 deaths. Maharashtra alone saw 19,034 cases and 55 deaths that year. Globally, the WHO documented more than 14.4 million dengue cases and 11,201 deaths in 2024. The disease imposes a financial weight as well. One Indian cost analysis found that a single state allocated roughly 16 million rupees for dengue materials and supplies in 2016, alongside 6.7 million rupees for vector-control activities and 4.9 million rupees in personnel costs. Multiply that across dozens of states and the expense becomes staggering—and that was before resistance forced cities to rethink their entire approach.

Dr. Shankar V, an internal medicine physician at Apollo Hospitals in Bengaluru, reframed the problem plainly: resistance does not mean municipalities should simply buy more insecticide. It means they must spend more intelligently. Repeatedly spraying an ineffective chemical has little epidemiological or economic value. The alternative is harder but potentially more durable. India already has a pipeline of options—pyriproxyfen and novaluron for larval control, Bti and spinosad as biological alternatives, and newer chemistries like isocycloseram that have shown promise internationally. But deployment depends on regulatory approval and evidence that these products actually work against locally resistant populations.

Dr. Amol Jaybhaye, an infectious-disease consultant at Narayana Health in Mumbai, acknowledged that the transition could initially cost more. Cities may need to expand monitoring, diversify their chemical arsenal, check for mosquitoes more frequently and focus interventions on specific neighborhoods rather than blanket the entire city. Yet he also emphasized that higher spending is not inevitable. Early detection of resistance, removal of breeding sites, larval control and judicious use of insecticides could help municipalities avoid wasting resources on chemicals that no longer work. The real shift is toward what public-health experts call Integrated Vector Management—combining biological controls, larvicides, environmental management, source reduction, targeted spraying and surveillance into a coordinated system.

This integrated approach would create demand for technologies that currently exist but remain unevenly deployed across Indian cities. Geographic information systems could map mosquito breeding sites and identify hotspots. Mobile reporting platforms could allow residents to flag standing water and potential breeding grounds. Artificial intelligence could analyze weather patterns, environmental data and dengue case clusters to predict where outbreaks are most likely. Some Indian cities are already adopting these tools. Others continue to rely on traditional methods. The gap reflects a deeper challenge: municipal readiness is uneven. Effective data-driven vector management requires trained personnel, functioning laboratories, digital infrastructure and sustained funding—resources not equally available across India's urban centers.

The economic calculus is complex. Upfront costs will likely rise. Municipalities will need to invest in laboratory testing, surveillance systems, trained staff and digital platforms. Yet both experts point to potential long-term savings. Better prevention could reduce infections, hospitalizations, lost productivity and the emergency spending that accompanies large outbreaks. As insecticide resistance reshapes what works and what does not, India's cities face a choice: continue spraying chemicals that are losing effectiveness, or build the surveillance and technological infrastructure to target interventions where they matter most. The emerging market will span alternative chemicals, biological controls, surveillance systems and predictive technologies. But the real transformation lies in treating dengue prevention as an integrated system rather than a spray-and-hope exercise.